Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.
Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.